A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

AK117

Subjects receive AK117 intravenously.

DRUG

Azacitidine

Subjects receive Azacitidine subcutaneously.

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou